We have successfully applied the platform for Indication Expansion, Drug Repositioning, Pathway Analysis, Target ID, and Clinical Trial Responder ID / Personalized Medicine, with top 5 pharma and biotech clients including Novartis, Merck and Bayer. BioXplor collaborates with academic teams for early stage drug discovery programs in oncology, including validation of predicted novel drug targets and novel drug designs in bioactivity assays and pre-clinical studies. BioXplor’s technology is available for licensing and we operate a CRO model.
Advisory Board: Dr. David Kwon, MD PhD (Harvard) MBA (UC Berkeley), former medical director at Novartis & Gilead, Prof. Jody Haigh, Haematology & Oncology, Department of Pharmacology and Therapeutics, University of Manitoba / CancerCare Manitoba, and Bill Allison, CTO at UC Berkeley.
Management Team: Mark Rogers, MSc (Molecular Biotech) is CEO and has a over 15 years experience in emerging biotechnology, previously Associate Director, Emerging Biotechnology Initiative at Merck KgaA. Pavel Kartasevs, MEng (Computer Engineering), MSc (Bioinformatics) is CTO, and has a specialised CompBio background combining high performance computing, bioinformatics and software engineering. Anna O'Leary, BA (Economics & Finance) is COO, and brings management, finance and business operations expertise to the team from Aramark and RBS Global Markets. John Conway, MSc (Data Science), is Head of Machine Learning at BioXplor, and brings over 20 years experience in hands-on analytics, data science and management in the Financial Industry to the team.